Samsung Biologics completes full acquisition of Samsung Bioepis

Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary First payment completed funded through paid-in capital Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON, South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologics...